MA52540A - Induction d'oligodendrocytes myélinisants dans des sphéroïdes corticaux humains - Google Patents

Induction d'oligodendrocytes myélinisants dans des sphéroïdes corticaux humains

Info

Publication number
MA52540A
MA52540A MA052540A MA52540A MA52540A MA 52540 A MA52540 A MA 52540A MA 052540 A MA052540 A MA 052540A MA 52540 A MA52540 A MA 52540A MA 52540 A MA52540 A MA 52540A
Authority
MA
Morocco
Prior art keywords
myelinizing
oligodendrocytes
induction
human cortical
cortical spheroids
Prior art date
Application number
MA052540A
Other languages
English (en)
Inventor
Mayur Madhavan
Zachary Nevin
Paul Tesar
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of MA52540A publication Critical patent/MA52540A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA052540A 2018-04-17 2019-04-16 Induction d'oligodendrocytes myélinisants dans des sphéroïdes corticaux humains MA52540A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658901P 2018-04-17 2018-04-17
US201862700472P 2018-07-19 2018-07-19

Publications (1)

Publication Number Publication Date
MA52540A true MA52540A (fr) 2021-02-24

Family

ID=66380185

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052540A MA52540A (fr) 2018-04-17 2019-04-16 Induction d'oligodendrocytes myélinisants dans des sphéroïdes corticaux humains

Country Status (6)

Country Link
US (1) US20210163888A1 (fr)
EP (1) EP3781674A1 (fr)
JP (2) JP2021521790A (fr)
CN (1) CN112469818A (fr)
MA (1) MA52540A (fr)
WO (1) WO2019204309A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7308710B2 (ja) * 2019-09-25 2023-07-14 株式会社日立ハイテクサイエンス 集束イオンビーム装置
EP4079843A4 (fr) * 2019-12-17 2023-05-31 Corestem Co., Ltd. Procédé de différenciation pour fournir une grande quantité d'oligodendrocytes par désassemblage d'organoïdes 3d générés à partir de cellules souches pluripotentes humaines
CN113564122B (zh) * 2021-08-05 2022-04-08 呈诺再生医学科技(珠海横琴新区)有限公司 人诱导性多能干细胞向少突胶质细胞分化的方法，试剂盒以及应用
JP2024538165A (ja) * 2021-10-15 2024-10-18 ナショナル ステムセル ファウンデーション オルガノイドを培養する方法及びシステム

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095730A1 (fr) * 2011-01-12 2012-07-19 Kido Tsuneo Procédé de culture pour obtenir et conserver une population pure ou enrichie de cellules souches neurales et/ou de cellules progénitrices neurales de mammifère qui sont susceptibles de se différencier en des cellules de lignée oligodentrocytique in vitro
US10301592B2 (en) * 2014-05-22 2019-05-28 New York Stem Cell Foundation, Inc. Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
WO2015186128A1 (fr) * 2014-06-02 2015-12-10 Kadimastem Ltd. Procédés d'induction de la myélinisation et de maturation des oligodendrocytes
LU92845B1 (en) * 2015-10-08 2017-05-02 Univ Du Luxembourg Campus Belval Means and methods for generating midbrain organoids
CN109789128A (zh) * 2016-07-27 2019-05-21 凯斯西储大学 促进髓鞘形成的化合物和方法
KR102598310B1 (ko) * 2017-04-13 2023-11-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인간 희소돌기아교세포 생성 및 시험관내 수초화 연구를 위한 개인화된 3d 신경 배양 시스템
CA3006897A1 (fr) * 2017-08-04 2019-02-04 University Health Network Generation de cellules progenitrices neurales oligodendrogeniques

Also Published As

Publication number Publication date
WO2019204309A1 (fr) 2019-10-24
EP3781674A1 (fr) 2021-02-24
US20210163888A1 (en) 2021-06-03
JP2021521790A (ja) 2021-08-30
JP2024084860A (ja) 2024-06-25
CN112469818A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
EP3727394A4 (fr) Organoïdes humains numérisés et méthodes d'utilisation de ceux-ci
EP3755805A4 (fr) Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
EP3562514A4 (fr) Thérapie génique pour le traitement de la maladie de wilson
EP3370617A4 (fr) Système non invasif d'imagerie et de traitement des arythmies cardiaques
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
EP3601285A4 (fr) Agent thérapeutique pour l'inhibition de la phosphodiestérase et ses troubles apparentés
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3429536A4 (fr) Traitement de l'ostéopénie et de l'ostéoporose et stimulation de la croissance osseuse
EP3668500A4 (fr) Méthodes de traitement de l'arthrose à l'aide d'un gel de cannabidiol transdermique
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
EP3528852C0 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3507371A4 (fr) Méthodes et compositions pour traiter des maladies et des troubles du système nerveux
MA52540A (fr) Induction d'oligodendrocytes myélinisants dans des sphéroïdes corticaux humains
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3902605A4 (fr) Méthodes et compositions pour traiter des troubles cutanés et capillaires
ZA201801300B (en) Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
IL269083A (en) Methods for preventing and treating heart disease
IL262508A (en) Methods and compositions for the treatment of degenerate bone
EP3849591A4 (fr) Méthodes et compositions pour traiter des maladies de la peau
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3720493C0 (fr) Combinaisons d'inhibiteurs de ripk1 et d'ikk pour la prévention ou le traitement de maladies immunitaires
MA54412A (fr) Traitement d'excès de graisse hépatique et/ou viscérale
EP4058017A4 (fr) Formulations médicamenteuses et méthodes de traitement de troubles métaboliques
EP3302464A4 (fr) Utilisation de cannabinoïdes dans le traitement de l'inflammation et/ou de la douleur oculaire